Safety and Efficacy Study of Adalimumab in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate

Inclusion Criteria:

• Met ACR criteria for diagnosis of active rheumatoid arthritis (RA) and have had atboth the Screening visit and Week 0 visit at least four swollen joints (out of 66assessed) and at least six tender joints(out of 68 assessed)

• Subjects must have failed prior treatment with one or more disease-modifyingantirheumatic drugs (DMARDs)

• DMARDs (other than methotrexate [MTX]) must have been discontinued for >= 28 days orat least 5 half-lives, whichever is greater, before the Week 0 visit

• Traditional Chinese Medicines must have been discontinued for >= 28 days before theWeek 0 visit

• Subjects must have received at least three months of treatment with MTX (minimum 7.5mg/week) and remained on a stable dose of MTX for >= 28 days prior to the Screeningvisit

• Glucocorticoids equivalent to <= 10 mg of prednisone and prednisone equivalent musthave remained unchanged for at least 28 days prior to the Week 0 visit

• Must have been able and willing to give written informed consent and to comply withthe requirements of this study protocol

Exclusion Criteria:

• A history of, or current, acute inflammatory joint disease of different origin (e.g.,mixed connective tissue disease, seronegative spondyloarthropathy, psoriaticarthritis, Reiter's syndrome, systemic lupus erythematosus, fibromyalgia or anyarthritide with onset prior to age 16 years

• Wheelchair-bound or bedridden

• Joint surgery involving joints to be assessed within this study, within two monthsprior to the Screening visit

• Intra-articular, intramuscular or intravenous administration of corticosteroids within 28 days prior to the Screening visit

• Prior treatment with any TNF antagonist, including adalimumab

• Subject considered by the investigator, for any reason, to be an unsuitable candidate

• Female subject who is pregnant or breast-feeding or considering becoming pregnant